Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.

Abstract: The present invention features a non-human animal model of malaria, e.g., Plasmodium, particularly Plasmodium falciparum. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.

Abstract: A process for preparing substantially dry GPC (glycerophosphocholine in enantiomeric form) from wet GPC without racemisation, comprises subjecting the wet GPC to reduced pressure and elevated temperature, to reduce the water content and give highly viscous GPC; adding ethanol or another suitable solvent and crystallising GPC therefore with cooling; filtering the crystalline GPC and removing solvent therefrom under reduced pressure; characterised in that the elevated temperature is at least 45.degree. C.; and the solvent is added to the highly viscous GPC. This process produces an apparently new form of L-.alpha.-Glycerophosphocholine, m.p. 148.degree.-152.degree. C.